Vu BT - Search Results

1

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.

Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Carvajal D, et al. Among authors: vu bt. Cancer Res. 2005 Mar 1;65(5):1918-24. doi: 10.1158/0008-5472.CAN-04-3576. Cancer Res. 2005. PMID: 15753391

2

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT. Tovar C, et al. Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11. Cancer Res. 2013. PMID: 23400593

3

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. Vassilev LT, et al. Among authors: vu bt. Science. 2004 Feb 6;303(5659):844-8. doi: 10.1126/science.1092472. Epub 2004 Jan 2. Science. 2004. PMID: 14704432

4

Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.

Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT. Thompson T, et al. Among authors: vu bt. J Biol Chem. 2004 Dec 17;279(51):53015-22. doi: 10.1074/jbc.M410233200. Epub 2004 Oct 6. J Biol Chem. 2004. PMID: 15471885 Free article.

5

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Tovar C, et al. Among authors: vu bt. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. doi: 10.1073/pnas.0507493103. Epub 2006 Jan 27. Proc Natl Acad Sci U S A. 2006. PMID: 16443686 Free PMC article.

6

Small-molecule inhibitors of the p53-MDM2 interaction.

Vu BT, Vassilev L. Vu BT, et al. Curr Top Microbiol Immunol. 2011;348:151-72. doi: 10.1007/82_2010_110. Curr Top Microbiol Immunol. 2011. PMID: 21046355 Review.

7

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, Liu JJ, Zhao C, Glenn K, Wen Y, Tovar C, Packman K, Vassilev L, Graves B. Vu B, et al. ACS Med Chem Lett. 2013 Apr 2;4(5):466-9. doi: 10.1021/ml4000657. eCollection 2013 May 9. ACS Med Chem Lett. 2013. PMID: 24900694 Free PMC article.

8

NMR structure of a complex between MDM2 and a small molecule inhibitor.

Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, Podlaski F. Fry DC, et al. Among authors: vu bt. J Biomol NMR. 2004 Oct;30(2):163-73. doi: 10.1023/B:JNMR.0000048856.84603.9b. J Biomol NMR. 2004. PMID: 15557803

9

Design of libraries targeting protein-protein interfaces.

Fry D, Huang KS, Di Lello P, Mohr P, Müller K, So SS, Harada T, Stahl M, Vu B, Mauser H. Fry D, et al. ChemMedChem. 2013 May;8(5):726-32. doi: 10.1002/cmdc.201200540. Epub 2013 Feb 21. ChemMedChem. 2013. PMID: 23436619

10

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.

Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N. Chu XJ, et al. Among authors: vu bt. J Med Chem. 2006 Nov 2;49(22):6549-60. doi: 10.1021/jm0606138. J Med Chem. 2006. PMID: 17064073

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters